Reflecting strong execution, we reported free cash flow of $698,000,000 for the full fiscal year 2023, Comprised of cash flow from operations of $823,000,000 less $124,000,000 in net capital expenditures and other. Full year reported free cash flow included non recurring restructuring payments of $20,000,000 which was not assumed in our annual free cash flow guidance $700,000,000 for fiscal 2023. Overall, we ended the fiscal year with a Strong balance sheet and a healthy cash balance of approximately $743,000,000 including aggregate borrowings of roughly 6 $50,000,000 Moreover, we have ample liquidity to support our ongoing business needs, while retaining the capacity to fund our future growth Strategy, including the acquisition of Stadia, which closed in November for a net cash consideration of $75,000,000 sorry, dollars 75,000,000 with additional consideration to be paid later based on achievements of certain performance metrics. Turning to capital allocation on Slide 23, We repurchased 155,000,000 of our shares in the 4th quarter and paid cash dividend of $52,000,000 Overall, we returned a total of $689,000,000 to shareholders through share This is in dividend in fiscal 2023, equating to almost 100% of reported free cash flow. Looking ahead, we expect Free cash flow of approximately $750,000,000 in fiscal 2024, which does not include remaining restructuring payments of approximately 20 $6,000,000 Our free cash flow outlook equates to a conversion rate of approximately 100% Relative to non GAAP net income and a healthy free cash flow yield of roughly 7.6% relative to Amdocs' current market capitalization.